“Evidence-based” appears on nearly every treatment provider’s website, including ours. It is worth asking what it actually means, because the term is used loosely enough to be close to meaningless – and because the honest version is more useful than the marketing one.
How addiction treatment has changed
The shift over the past few decades has been from treating addiction as a moral or willpower problem to treating it as what NIDA describes as a “complex, treatable chronic medical condition.”
That reframing carries a practical consequence people often miss. In chronic illness, relapse is not treatment failure. NIDA puts it directly: “as with many other chronic illnesses, relapse or return to drug use after a period of abstinence is often part of the treatment and recovery process” – an indication to revise the plan rather than evidence that treatment didn’t work.
What “evidence-based” actually means
Strictly, it means an approach has been tested in controlled research and shown to produce better outcomes than a comparison condition. In practice it is often used to mean “we use recognised methods,” which is not the same claim.
Two things worth knowing before you evaluate anyone’s claim.
Effect sizes in this field are modest. When NIDA’s own treatment principles were meta-analysed, supported approaches produced effect sizes between roughly 0.11 and 0.36 – real and replicated, but not transformative. Anyone describing a single modality as a breakthrough is overselling it.
Not every widely-held principle survived testing. Of seven principles examined, five were supported. Two were not – one of them being the assumption that longer treatment produces better results. On that analysis, programmes of twelve weeks or more produced “virtually the same drug use outcomes” as shorter ones.
That finding deserves care rather than dismissal. It doesn’t mean length never matters, and individual circumstances vary enormously. It does mean that “longer is better” is an assumption rather than an established fact, and it’s reasonable to ask a provider why they recommend the duration they recommend.
What the research does support
The approaches that held up in the meta-analysis:
- Therapeutic communities – the largest effect found (g = 0.36)
- Contingency management – structured, tangible reinforcement for verified abstinence (g = 0.21)
- Cognitive behavioural therapy – g = 0.11
- Matching treatment to the individual’s needs rather than applying one programme uniformly (g = 0.24)
- Addressing multiple needs concurrently – medical, psychiatric, housing, legal, family
- Reassessing and revising the treatment plan as circumstances change (g = 0.25)
The pattern is worth noticing: several of the strongest findings are about how treatment is organised – matched, comprehensive, revised – rather than which named therapy is used.
Medications
For some substances, medication is standard care rather than an optional extra.
“There are FDA approved medications to treat some, but not all, substance use disorders. For example, treatment with methadone, buprenorphine, or naltrexone is standard of care for opioid use disorder.” Medications also exist for alcohol use disorder and smoking cessation, and lofexidine is used for opioid withdrawal symptoms.
For stimulants and cannabis there are currently no FDA-approved medications – researchers “are actively working to develop compounds” for them. A provider claiming a medication breakthrough for cocaine or methamphetamine is ahead of the evidence.
In opioid treatment, medication and behavioural therapy are typically used together rather than as alternatives.
How outcomes get measured
This is where claims become hard to compare, and where scepticism is warranted.
“Success rate” has no standard definition in this industry. It may mean completion of the programme, abstinence at discharge, abstinence at some follow-up point, or improvement on a measure. Rates quoted without a definition, a follow-up interval, and a denominator are not comparable to anything – and are often not verifiable at all.
Follow-up length matters most. Outcomes measured at discharge and outcomes measured at twelve months are different questions, and only the second one tells you much.
What to ask a provider
Reasonable questions, all of which good programmes can answer:
- Which specific therapies do you use, and what’s the evidence for them in my situation?
- Do you offer medication where it’s indicated? For opioid use disorder in particular, a programme that doesn’t should explain why.
- How do you assess and treat co-occurring mental health conditions?
- How is the treatment plan reassessed, and how often? Reassessment is one of the supported principles.
- How do you define and measure your outcomes, and over what follow-up period?
- Why this length of stay for me specifically?
- What happens after discharge?
A provider who answers these clearly and without defensiveness is telling you something useful regardless of the specific answers. If co-occurring conditions are part of the picture, our article on dual diagnosis covers why treating both at once matters.
If you’re trying to make sense of treatment options for addiction, you don’t have to work through it alone. Choice House offers inpatient residential treatment and transitional sober living for men in Boulder, Colorado, with care for co-occurring mental health conditions alongside substance use. Call 720-577-4422 or reach out through our website to talk it through and find out what options might help.